Systemic Progesterone Should NOT Be Prescribed to Patients with a History of ER+ Breast Cancer
Systemic progesterone is absolutely contraindicated in patients with a known history of breast cancer, including estrogen receptor-positive disease. This is an FDA-mandated contraindication that supersedes any theoretical benefits 1.
Primary Evidence: FDA Contraindication
The FDA drug label for progesterone explicitly lists "known, suspected, or history of breast cancer" as an absolute contraindication 1. This is not a relative contraindication or a "use with caution" scenario—it is a complete prohibition based on regulatory safety standards.
Supporting Rationale
Breast Cancer Risk Data
The Women's Health Initiative (WHI) trials demonstrated that estrogen plus progestin therapy significantly increases breast cancer risk:
- Relative risk of invasive breast cancer: 1.24 (95% CI, 1.01-1.54)
- Absolute risk: 41 versus 33 cases per 10,000 women-years compared to placebo
- Among women with prior hormone therapy use, the relative risk increased to 1.86 1
Critically, invasive breast cancers in the estrogen plus progestin group were larger, more likely to be node-positive, and diagnosed at more advanced stages 1. This demonstrates not just increased incidence but worse tumor biology.
Duration of Risk
The increased breast cancer risk persists for >10 years after discontinuation of estrogen plus progestin therapy 1. This prolonged risk window means that even if a patient's breast cancer is considered "cured," introducing systemic progesterone could reactivate dormant disease or promote new tumor development.
Mechanistic Concerns
Recent research confirms that progesterone receptor (PR) signaling actively drives tumor growth in ER+ breast cancer:
- Both estradiol and progesterone independently increase tumor growth in ER+ xenograft models
- PR is required for tumor growth in patient samples and is sufficient to drive tumor growth and metastasis even when ER signaling is ablated 2
- Women with current or past ER+ breast cancer should avoid all sex hormones, including progesterone 3
Clinical Pitfalls to Avoid
Do not rationalize progesterone use for menopausal symptoms in breast cancer survivors, even if symptoms are severe. Non-hormonal alternatives exist (SSRIs, SNRIs, gabapentin) 4
Do not confuse vaginal estrogen with systemic progesterone—while vaginal estrogens have limited systemic absorption and may be cautiously considered in specific circumstances, systemic progesterone has no such safety profile in breast cancer patients 4
Do not assume "natural" progesterone is safer than synthetic progestins—the FDA contraindication applies to all progesterone formulations 1
Do not prescribe based on time since diagnosis—the contraindication applies regardless of how long ago the breast cancer was treated, given the prolonged risk window
Alternative Management
For menopausal symptoms in breast cancer survivors, prioritize:
- SSRIs/SNRIs (venlafaxine, desvenlafaxine, paroxetine)
- Gabapentin for hot flashes (may have fewer discontinuation symptoms than SSRIs)
- Non-hormonal vaginal lubricants (Replens) for vaginal dryness
- Vaginal estriol preparations (if absolutely necessary for severe atrophic vaginitis, and only after oncology consultation) 4